| Nov 19 |
Spyre Therapeutics announces pricing of $200 million public offering of common stock
|
| Nov 19 |
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
|
| Nov 18 |
Spyre Therapeutics announces proposed secondary offering
|
| Nov 18 |
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
|
| Nov 12 |
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potentia...
|
| Nov 11 |
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024
|
| Nov 8 |
Spyre Therapeutics GAAP EPS of -$1.36
|
| Nov 7 |
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Oct 30 |
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
|
| Oct 14 |
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
|
